The efficacy and safety of lenalidomide plus dexamethasone in relapsed and/or refractory multiple myeloma patients with impaired renal function. - Wikidata - wikimedia - TriplyDB

The efficacy and safety of lenalidomide plus dexamethasone in relapsed and/or refractory multiple myeloma patients with impaired renal function.

The efficacy and safety of lenalidomide plus dexamethasone in relapsed and/or refractory multiple myeloma patients with impaired renal function.

http://www.wikidata.org/entity/Q33390284

about

Current Trends of Renal Impairment in Multiple Myeloma The Prevalence and Management of Multiple Myeloma-Induced Kidney Disease in China Use of lenalidomide in the management of relapsed or refractory multiple myeloma: expert recommendations in Korea International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation Carfilzomib and pomalidomide in patients with relapsed and/or refractory multiple myeloma with baseline risk factors Management of the adverse effects of lenalidomide in multiple myeloma.The clinical safety of lenalidomide in multiple myeloma and myelodysplastic syndromes.Renal impairment is not an independent adverse prognostic factor in patients with multiple myeloma treated upfront with novel agent-based regimens.Lenalidomide for the treatment of relapsed and refractory multiple myeloma.A multicenter, open-label, phase 2 study of lenalidomide plus low-dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma: the MM-021 trial Lenalidomide and dexamethasone for acute light chain-induced renal failure: a phase II study.Lenalidomide plus low-dose dexamethasone in Chinese patients with relapsed or refractory multiple myeloma and renal impairment.Spotlight on lenalidomide in relapsed or refractory multiple myeloma.Lenalidomide in multiple myeloma-a practice guideline.Improvement in renal function and its impact on survival in patients with newly diagnosed multiple myeloma.Pharmacokinetics, metabolism and excretion of [(14)C]-lenalidomide following oral administration in healthy male subjects.Diagnosis and treatment of multiple myeloma and AL amyloidosis with focus on improvement of renal lesion.Impact of renal impairment on outcomes with lenalidomide and dexamethasone treatment in the FIRST trial, a randomized, open-label phase 3 trial in transplant-ineligible patients with multiple myeloma Lenalidomide in combination with dexamethasone in elderly patients with advanced, relapsed or refractory multiple myeloma and renal failure.Optimizing the use of lenalidomide in relapsed or refractory multiple myeloma: consensus statement.Multiple myeloma treatment strategies with novel agents in 2011: a European perspective Lenalidomide: a review of its use in the treatment of relapsed or refractory multiple myeloma.Treatment strategies in relapsed and refractory multiple myeloma: a focus on drug sequencing and 'retreatment' approaches in the era of novel agents.Safety and efficacy of lenalidomide in relapsed or refractory multiple myeloma.Novel approaches for reducing free light chains in patients with myeloma kidney.Evaluation of the pharmacokinetics, preclinical, and clinical efficacy of lenalidomide for the treatment of multiple myeloma.Current treatments for renal failure due to multiple myeloma.Lenalidomide in patients with POEMS syndrome: a systematic review and pooled analysis.Current strategies for treatment of relapsed/refractory multiple myeloma.Multiple Myeloma: Cast Nephropathy, VTE, and Neurologic Complications.Lenalidomide with dexamethasone treatment for relapsed/refractory myeloma patients in Korea-experience from 110 patients.An update in treatment options for multiple myeloma in nontransplant eligible patients.Recent advances in the pathogenesis and management of cast nephropathy (myeloma kidney).Bridging the Divide: An Onco-Nephrologic Approach to the Monoclonal Gammopathies of Renal Significance.Managing renal complications in multiple myeloma.Update on elotuzumab, a novel anti-SLAMF7 monoclonal antibody for the treatment of multiple myeloma.Current treatments for renal failure due to multiple myeloma.Treatment of Relapsed/Refractory Multiple Myeloma.Current treatment strategies with lenalidomide in multiple myeloma and future perspectives.Pharmacokinetics, safety, and efficacy of lenalidomide plus dexamethasone in patients with multiple myeloma and renal impairment.

P2860

Q26740444-C84F7308-8A6E-4EFE-A0FC-153DFD3324E9 Q26740446-51078CC2-0D09-46AB-A89E-7A80AB77EC01 Q26992002-12C464AE-4A0A-4C32-814E-40286BC997C2 Q27002668-88626BAD-CF1D-44D6-BC45-CDE36D6D2621 Q28084683-703940BA-DB39-40FC-95C4-A4196B7BF483 Q33394632-0A45554B-32CF-46BA-ACB5-7AF979CE78E0 Q33398044-EAAADCAF-6E35-4B21-9E63-4E6089369E38 Q33398587-C8364662-B362-4ADC-87F7-F77981224565 Q33403183-67FCD44D-3DA2-4B4C-A951-E6E01767645B Q33408494-850D9362-B184-4A7A-B472-474A33575106 Q33418712-C5C697E9-A10D-4504-8948-5F355DEB64AA Q33421008-065191CF-BC3F-4A10-BAD0-3F248660D064 Q34028642-971FC4D2-2950-4B7A-B3C5-FB2D716B0787 Q34656086-C5215C23-3102-4058-AD4B-DAD0DCEB3C84 Q35244883-7D107F00-FB95-4324-8AB5-916E1A9E8187 Q35777792-189E4B64-D307-4AFF-8E40-FE6DF401647F Q36301287-AD71DA5F-89C0-4381-BBF8-997B4357DEE8 Q36750472-E6248C4C-00E4-4306-B015-732A3326C1FE Q36934144-AC26B5A2-A6C1-4CDB-BD95-B90D5E7B75CF Q37835695-2CBED233-D7C9-420A-9998-6F738F483F7D Q37858327-D1AB1522-FD9F-41FA-B548-2D42AF92CDEE Q37858523-2FD71A77-579E-4406-8525-9E21E64A26FF Q37949201-C10C5E3E-255D-4097-859B-EA88F81379EC Q37976672-62EB1F72-0522-4D2B-BF07-EE3B72DDEDD1 Q37986358-9BEBE34F-1252-44A3-82FC-18A9C13287B8 Q38031989-4CC5BC6D-3106-4224-84A2-9EBAB8A99C61 Q38109235-B291E1D4-740E-483E-914E-E2A63180D041 Q38167836-B1C1FEC8-D791-4A49-AB64-4A1E6B3B7111 Q38182683-7C4EF6C1-716A-474F-8258-DFA0047A70C1 Q38230423-426D6F64-C864-4A71-96C3-0692EA5A970F Q38446990-63AC490F-7399-4057-A622-F1EB6C48EABA Q38561373-1970BBDE-B71F-4918-BD17-E88077A729E1 Q38802354-95E76364-C638-45C8-8E5D-1CD7C8C9318D Q38896793-98C63AF0-8E20-4AD2-895C-55468410430A Q38900024-FF341D4E-0DDB-4AC2-93FC-DEFBF74BC5BC Q38929980-02165998-5942-4A9F-8118-63D21CAA9A94 Q38959138-5EFC0A7E-8BE9-45F2-B321-D93A18EF3DC0 Q38970597-A1733424-206E-451E-8484-0155D41C8D64 Q39524467-BB2B4CA1-F3D1-4C04-9CD2-2E504C1F5659 Q39692801-EA2386CB-513F-46FE-83AC-ECB8590C933F

P2860

The efficacy and safety of lenalidomide plus dexamethasone in relapsed and/or refractory multiple myeloma patients with impaired renal function.

http://www.wikidata.org/entity/Q33390284

description

2010 nî lūn-bûn

@nan

2010 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年学术文章

@wuu

2010年学术文章

@zh-cn

2010年学术文章

@zh-hans

2010年学术文章

@zh-my

2010年学术文章

@zh-sg

2010年學術文章

@yue

name

The efficacy and safety of len ...... with impaired renal function.

@ast

The efficacy and safety of len ...... with impaired renal function.

@en

type

label

The efficacy and safety of len ...... with impaired renal function.

@ast

The efficacy and safety of len ...... with impaired renal function.

@en

prefLabel

The efficacy and safety of len ...... with impaired renal function.

@ast

The efficacy and safety of len ...... with impaired renal function.

@en

P1433

Q33390284-B06A422C-F1AE-4D78-ACEC-8990519E7690

P1476

Q33390284-F49890C0-F980-42C0-BB8C-94A90A5A15E1

P2093

Q33390284-13C63C80-D82F-4154-A4EA-06BE1162BCB6

Q33390284-23A92570-76B4-4604-BC0C-36D5FC634C20

Q33390284-34F02CB3-9786-4C8F-9071-438DA725FBB8

Q33390284-47EB4596-B024-4C59-B333-18834AD444AF

Q33390284-502D20EB-2DC8-4A00-AABE-46A6C88541E4

Q33390284-5478B9E0-AECD-4D65-860B-72467EC04A14

Q33390284-8BA4C9B6-AC2A-4CCC-9BE0-7DACD31AA948

Q33390284-D76D1BFB-9204-4CB6-8205-BE5465D12B91

Q33390284-DE40172E-BC17-4C99-AEF5-0D3AB0708EF0

P2860

Q33390284-359409CF-FABF-4836-9777-29E2B4626565

Q33390284-432DCD7A-860D-432D-BBFB-E47A136A0775

Q33390284-47B1EBE8-AD22-4A17-A9C2-E2B3620A759C

Q33390284-47DF29C7-F118-4B8C-ACDB-F086232FEEC4

Q33390284-4AA9CBA1-399B-4D24-B379-A7946F4960B5

Q33390284-803177DD-9396-4187-86E4-DE663B1D1FBA

Q33390284-8E0E7109-E6BB-47C5-89CA-44E0975FFFC1

Q33390284-90A0889A-F985-4A5E-A84B-9584F153FAFC

Q33390284-915F014B-3DD7-4DA8-9DB8-B8688660C19E

Q33390284-C11D8F29-09F8-46A0-81FB-1BE66A75EFB8

P304

Q33390284-8C43295D-9113-4FF0-9AAA-C820DBBA99B0

P31

Q33390284-BB77521A-B74F-4E4C-8A3E-F89AB154D2D3

P356

Q33390284-A8FE764E-6ACD-4EA7-8904-57A0286EDB30

P407

Q33390284-EC55F6A3-6039-4644-BB3E-E277D650C49E

P433

Q33390284-206D6F4B-ED46-4721-8E74-011BEBBEBA9B

P478

Q33390284-63B4805F-5132-4E1D-A019-72AD4B0D95F1

P50

Q33390284-106272AB-E95A-47A9-9666-ECAEB4CEFB07

Q33390284-E69A92E9-3942-4F2B-823E-C815100BF839

P577

Q33390284-F2178EF1-A7B2-4B78-B524-E744328858FC

P5875

Q33390284-2FE1AEF5-0BA7-4857-BBC6-3A96EC0106E5

P698

Q33390284-BECFF9C9-3391-4B80-8C23-0AD7B01F887D

P921

Q33390284-0DEF87F8-6C11-457F-8724-5410DF41033C

Q33390284-CB45F715-8CC7-46A0-B336-68B1396CB37E

P932

Q33390284-D1333E91-73F4-41E0-8001-CDF8DA6DD8BF

P356

P1433

P1476

The efficacy and safety of len ...... with impaired renal function.

@en

P2093

Adrian Alegre

http://www.w3.org/2001/XMLSchema#string

Carlos M de Castro

http://www.w3.org/2001/XMLSchema#string

Donna M Weber

http://www.w3.org/2001/XMLSchema#string

Donna Reece

http://www.w3.org/2001/XMLSchema#string

Edward A Stadtmauer

http://www.w3.org/2001/XMLSchema#string

Jeffrey A Zonder

http://www.w3.org/2001/XMLSchema#string

Marta Olesnyckyj

http://www.w3.org/2001/XMLSchema#string

Zhinuan Yu

http://www.w3.org/2001/XMLSchema#string

Zvenyslava Masliak

http://www.w3.org/2001/XMLSchema#string

P2860

Clinical review: specific aspects of acute renal failure in cancer patients

Bortezomib-dexamethasone combination in a patient with refractory multiple myeloma and impaired renal function.

Renal failure in multiple myeloma: incidence, correlations, and prognostic significance.

Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.

International uniform response criteria for multiple myeloma.

Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.

Pathogenesis and treatment of renal failure in multiple myeloma.

Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant.

Renal pathologic spectrum in an autopsy series of patients with plasma cell dyscrasia.

Renal, hematologic and infectious complications in multiple myeloma.

P304

3807-3814

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/CNCR.25139

http://www.w3.org/2001/XMLSchema#string

P407

P433

16

http://www.w3.org/2001/XMLSchema#string

P478

116

http://www.w3.org/2001/XMLSchema#string

P50

Hartmut Goldschmidt

Meletios A. Dimopoulos

P577

2010-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

44688655

http://www.w3.org/2001/XMLSchema#string

P698

20564094

http://www.w3.org/2001/XMLSchema#string

P921

P932

2970911

http://www.w3.org/2001/XMLSchema#string